Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Carbonylation. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
This patent reveals a streamlined Pd-catalyzed carbonylation for 3-benzylidene-2,3-dihydroquinolone, offering enhanced scalability and cost reduction in pharmaceutical intermediate manufacturing.
Patent CN117164506B enables scalable, high-yield synthesis of indeno[1,2-b]indole-10(5H)-one with simplified purification, offering cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN112538054B details a novel Pd-catalyzed route for 1,2,4-triazole-3-one compounds, offering high efficiency and broad substrate scope for pharmaceutical manufacturing.
Patent CN115260188B enables scalable, cobalt-catalyzed synthesis of tetrahydro-beta-carboline ketones with high substrate tolerance and simplified purification, offering supply chain resilience for pharmaceutical intermediates.
Patent CN112239456B enables efficient synthesis of high-purity pharmaceutical intermediates through palladium-catalyzed carbonylation with simplified process and enhanced supply chain reliability.
Innovative nickel-catalyzed method eliminates toxic sulfur sources and achieves high functional group tolerance for cost-effective pharmaceutical intermediate production.
Patent CN114751883B introduces a novel carbonylation method for benzofuran-3-carboxamide synthesis, enhancing purity and reducing costs in pharmaceutical intermediate manufacturing through simplified process design and improved scalability.
Patent CN119823040A enables efficient one-step production of high-purity dihydroisoquinolinone derivatives through palladium catalysis with TFBen CO source.
This patent reveals a novel one-step palladium-catalyzed carbonylation method for indolo[2,1a]isoquinoline synthesis with enhanced substrate tolerance and simplified manufacturing processes enabling reliable pharmaceutical intermediate supply chains.
Patent CN112480015B introduces an innovative one-pot method for synthesizing trifluoromethyl quinazolinones with enhanced scalability and cost reduction potential for pharmaceutical intermediate production.
Novel palladium-catalyzed methodology enables efficient production of high-purity quinazolinone intermediates with enhanced scalability and cost reduction for pharmaceutical manufacturing.
Novel palladium-catalyzed method using benzisoxazole as dual source enables high-yield synthesis with simplified supply chain and reduced manufacturing costs.
Patent-CN-7 introduces an efficient one-step palladium-catalyzed method for indolo[2,1a]isoquinoline synthesis offering significant cost reduction and scalable production capabilities.
Patent CN115286556B enables high-purity indolinone ester production using green solvents and catalysts, reducing lead time while enhancing supply chain reliability for pharma intermediates.
Patent CN115286553B introduces a novel nickel-catalyzed carbonylation method for indole compounds offering simplified synthesis and enhanced supply chain reliability for pharmaceutical intermediates.
Patent CN115246786B enables efficient synthesis of indole and benzoxazine intermediates through palladium catalysis with simplified operations and scalable production for high-purity pharmaceutical applications.
Patent CN117164544A enables cost-effective pyrone derivative synthesis using palladium catalysis with enhanced scalability and purity for pharmaceutical manufacturing supply chains.
This patent reveals a novel palladium-catalyzed method for pyrrolinone intermediate synthesis enabling high-purity pharmaceutical compounds with simplified scale-up and enhanced supply chain reliability for global manufacturers.
Breakthrough one-pot palladium-catalyzed method for high-purity 2-trifluoromethyl quinazolinone with scalable manufacturing and enhanced supply chain reliability for pharmaceutical applications.
Patent CN120208841A introduces a mild carbonylation method using formic acid instead of toxic CO gas enabling cost-effective scale-up for pharmaceutical intermediates with exceptional functional group tolerance.